RECRUITING

Reduction of Adverse Drug Events and Readmissions

Conditions

Pharmacogenomic Testing for Medication Management

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.

Official Title

Pharmacogenomic Test Assessment for Medication Management in the Advancement of Medicine

Quick Facts

Study Start:2019-03-15

Study Completion:2026-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT02738047

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:25 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Male or female patients of 25 years of age or older who are able to give their written Informed Consent to participate in a Clinical Study based on voluntary agreement with a thorough explanation of the patient's participation will be provided to them. 2. Patient underwent PGx testing for alleles appropriate to the target drugs within the prior 120 days ("index PGx test assessment"); 3. Patient was receiving at least one medication known to be associated with allelic variation at the time of the ("index PGx test assessment"), including over-the- counter medications; 4. Patient has a history of at least one TDAE over the 24-month period preceding the PGx test assessment, or has experienced inadequate efficacy from a target drug. 1. Patient is currently hospitalized; 2. Patient's medical and medication history is unavailable over the 120-day period preceding the PGx test assessment; 3. Patient is unable to provide an accurate history due to mental Incapacity; 4. Patient is known to have undergone prior PGx testing for genes specific to the target drug(s), exclusive of the PGx test relating to this Study.	Pregnancy or breastfeeding Severe psychiatric disorders Active substance abuse Unstable medical conditions Inability to comply with study requirements

Inclusion Criteria

Exclusion Criteria

1. Male or female patients of 25 years of age or older who are able to give their written Informed Consent to participate in a Clinical Study based on voluntary agreement with a thorough explanation of the patient's participation will be provided to them.
2. Patient underwent PGx testing for alleles appropriate to the target drugs within the prior 120 days ("index PGx test assessment");
3. Patient was receiving at least one medication known to be associated with allelic variation at the time of the ("index PGx test assessment"), including over-the- counter medications;
4. Patient has a history of at least one TDAE over the 24-month period preceding the PGx test assessment, or has experienced inadequate efficacy from a target drug.
1. Patient is currently hospitalized;
2. Patient's medical and medication history is unavailable over the 120-day period preceding the PGx test assessment;
3. Patient is unable to provide an accurate history due to mental Incapacity;
4. Patient is known to have undergone prior PGx testing for genes specific to the target drug(s), exclusive of the PGx test relating to this Study.

Pregnancy or breastfeeding
Severe psychiatric disorders
Active substance abuse
Unstable medical conditions
Inability to comply with study requirements

Contacts and Locations

Study Contact

Diana Messir

CONTACT

239-908-0412

Diana@integritycro.com

Diana M Messir

CONTACT

239-908-0412

Diana.M@Radar-PGxStudy.com

Principal Investigator

Haleh Farzanmehr, MD

PRINCIPAL_INVESTIGATOR

GXL

Haleh Farzanmehr, MD

STUDY_DIRECTOR

GXL

Study Locations (Sites)

MD@Home

York, Pennsylvania, 17402

United States

Collaborators and Investigators

Sponsor: ClinLogic LLC

Haleh Farzanmehr, MD, PRINCIPAL_INVESTIGATOR, GXL
Haleh Farzanmehr, MD, STUDY_DIRECTOR, GXL

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-03-15

Study Completion Date2026-12

Study Record Updates

Study Start Date2019-03-15

Study Completion Date2026-12

Terms related to this study

Additional Relevant MeSH Terms

Pharmacogenomic Testing for Medication Management